Rockefeller Capital Management
IMRX icon

Rockefeller Capital Management’s Immuneering IMRX Stock Holding History

Rockefeller Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-177,377
Closed -$390K – 1700
2024
Q4 		$390K Buy
+177,377
New +$368K ﹤0.01% 1537

Other funds holding IMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Southport Management Wilson, Wyoming $28.6M AUM 41.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rockefeller Capital Management's IMRX Position: Q1 2025 in Review

Rockefeller Capital Management sold out of Immuneering (IMRX) in Q1 2025, closing a stake of 177,377 shares — an estimated $390K sold.

Rockefeller Capital Management first reported a position in IMRX in Q4 2024 and held it in 1 quarter. The position peaked at $390K in Q4 2024. 35 funds tracked by Wall St. Rank hold IMRX as of Q1 2025.

  • Rockefeller Capital Management reported no remaining Immuneering position as of Q1 2025 after selling out during the quarter.
  • Rockefeller Capital Management sold 177,377 Immuneering shares in Q1 2025, an estimated $390K.
  • Rockefeller Capital Management first reported a position in Immuneering in Q4 2024 and held it in 1 quarter.
  • Rockefeller Capital Management's Immuneering position peaked at $390K in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Immuneering as of Q1 2025.

Based on Rockefeller Capital Management's 13F filing for Q1 2025, filed 14 May 2025.